By Laura Kemp •
Published: 30 Jun 2020 • 9:59
GILEAD: PHARMA COMPANY
Credit: Twitter @jhontxu
THE drug, created by the American pharmaceutical company Gilead, announced that governments in developed countries could expect to pay $390 for a vial, which would equate to around €2,082 per patient and longer therapies could cost up to €3,818.
Hospitals have been using this medication, which was donated by Gilead, since May but they will begin charging for their services in July. This is the first drug approved by the European Medicine Agency as a Covid-19 remedy.
The drug is expected to shorten recovery time and stems from an experimental therapy that began in 2009 to try and treat Ebola. The drug is an antiviral medicine which slows down the production of new particles, and therefore the illness develops less quickly and patients recover an average of four days earlier than usual.
Share this story
Subscribe to our Euro Weekly News alerts to get the latest stories into your inbox!
By signing up, you will create a Euro Weekly News account if you don't already have one. Review our
Originally from UK, Laura is based in Axarquia and is a writer for the Euro Weekly News covering news and features.
Got a news story you want to share? Then get in touch at firstname.lastname@example.org.
Download our media pack in either English or Spanish.